Replies to post #26907 on Marker Therapeutics Inc (MRKR)

[rfj1862]

Possibly, but it is always problematic to use inflated buyout prices in past hype periods for future predictions. I don't think Gilead and especially Celgene would pay that much again today.

I know for a fact that these acquisitions, and the prices paid, were predicated on the hope that CAR-T would be effective in solid tumors, which hasn't really panned out, at least not yet.